425: Helix Acquisition Corp. II Announces Business Combination Agreement with BridgeBio Oncology Therapeutics

Helix Acquisition Corp. II will merge with BridgeBio Oncology Therapeutics, a clinical-stage biopharmaceutical company, to advance novel small molecule therapeutics targeting RAS and PI3Ka malignancies.

Summary

• Helix Acquisition Corp. II (Helix) has entered into a Business Combination Agreement with BridgeBio Oncology Therapeutics (BBOT) on February 28, 2025.
• Helix will de-register in the Cayman Islands and domesticate as a Delaware corporation.
• Following the Domestication, Merger Sub will merge with BBOT, making BBOT a wholly-owned subsidiary of Helix.
• Upon Domestication, Helix is expected to change its name to BridgeBio Oncology Therapeutics, Inc.
• The Aggregate Merger Consideration will be determined by dividing $461,051,546 (Equity Value) by the Redemption Price.
• The executive management team of BBOT is expected to serve as the executive management team of PubCo following the Closing.
• PubCo's board will consist of seven members, with the Sponsor initially designating two directors.
• Closing is expected to occur following the fulfillment or waiver of closing conditions.
• The Registration Statement is expected to be filed promptly after the date of the Business Combination Agreement.

Sentiment

Score: 7

Explanation: The document is a formal announcement of a business combination, which is generally viewed positively as it provides growth opportunities for both companies. The sentiment is neutral to positive.

Positives

• The merger provides BBOT with access to public markets and capital to advance its pipeline.
• Existing Helix shareholders subscribed for approximately $188,000,000 of the PIPE Investments, which includes Cormorants subscription for an aggregate of $75,000,000 of PIPE Investments.
• The combined company will have a focused pipeline targeting significant unmet needs in oncology.
• BBOT's experienced management team will lead the combined company.
• The transaction includes support agreements from key Helix and BBOT shareholders.

Negatives

• The Sponsor will forfeit Class B Shares and potentially Contribution Shares if Helix Closing Cash is less than $400,000,000.
• The Business Combination Agreement may be terminated under certain circumstances, including if the Closing has not occurred by October 31, 2025 (potentially extended to December 31, 2025).

Risks

• The closing is subject to customary conditions, including regulatory approvals and shareholder approval.
• The combined company's success depends on the clinical and commercial success of BBOT's product candidates.
• The market for biopharmaceutical products is highly competitive.
• The amount of redemption requests made by Helix's public shareholders could impact the available cash for the combined company.
• There are risks relating to any legal proceedings that may be instituted against Helix, the combined company or others following the announcement of the Business Combination.

Future Outlook

The combined company will focus on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies.

Industry Context

The announcement reflects the ongoing trend of SPACs merging with promising biotech companies to accelerate drug development and commercialization.

Comparison to Industry Standards

• Comparable companies in the biopharmaceutical sector that have gone public via SPAC mergers include companies such as Tango Therapeutics and Relay Therapeutics.
• These companies also focus on targeted cancer therapies.
• The $461 million valuation is within the range of similar transactions in the biotech SPAC market.
• The success of the merger will depend on the clinical trial outcomes and regulatory approvals of BBOT's drug candidates, similar to other clinical-stage biopharma companies.

Stakeholder Impact

• Shareholders of Helix will have their shares converted into shares of the combined company.
• BBOT stockholders will receive shares of PubCo Common Stock.
• Employees of BBOT are expected to become employees of the combined company.
• The combined company will continue to develop and commercialize cancer therapeutics, potentially benefiting patients.

Next Steps

• File the Registration Statement with the SEC.
• Mail a definitive proxy statement/prospectus to Helix shareholders.
• Hold a Helix Shareholders Meeting to vote on the Business Combination.
• Fulfill or waive the closing conditions set forth in the Business Combination Agreement.
• Complete the Domestication and Merger.

Key Dates

Keywords

business combination, merger, biopharmaceutical, oncology, therapeutics, SPAC, RAS, PI3Ka, PIPE Investment, redemption, clinical stage